Published in Int J Mol Sci on May 27, 2014
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2015) 0.97
Review on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor Treatment. Evid Based Complement Alternat Med (2015) 0.81
Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences. J Proteome Res (2016) 0.77
Triple-controlled oncolytic adenovirus expressing melittin to exert inhibitory efficacy on hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.77
The Chinese Herb Jianpijiedu Contributes to the Regulation of OATP1B2 and ABCC2 in a Rat Model of Orthotopic Transplantation Liver Cancer Pretreated with Food Restriction and Diarrhea. Biomed Res Int (2015) 0.76
The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget (2016) 0.76
Evaluation of total hepatocellular cancer lifespan, including both clinically evident and preclinical development, using combined network phenotyping strategy and fisher information analysis. Semin Oncol (2015) 0.75
Liver regeneration microenvironment of hepatocellular carcinoma for prevention and therapy. Oncotarget (2017) 0.75
Restoration of miR-20a expression suppresses cell proliferation, migration, and invasion in HepG2 cells. Onco Targets Ther (2016) 0.75
Expression and diagnostic value of CCT3 and IQGAP3 in hepatocellular carcinoma. Cancer Cell Int (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
Hepatocellular carcinoma. Lancet (2003) 22.54
Hepatocellular carcinoma. Lancet (2012) 18.09
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol (1996) 15.20
Hedgehog signaling in animal development: paradigms and principles. Genes Dev (2001) 14.75
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Cell-cycle checkpoints and cancer. Nature (2004) 13.19
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer (1954) 12.77
Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 11.21
T cell exhaustion. Nat Immunol (2011) 11.08
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer (1999) 8.61
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta (2003) 7.85
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
Liver regeneration. Hepatology (2006) 7.52
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature (2013) 7.51
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer (1988) 7.05
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. JAMA (2012) 6.80
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med (1997) 6.03
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology (2006) 4.61
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 4.60
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology (2002) 4.34
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene (2002) 4.15
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem (1995) 3.69
Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology (2000) 3.42
Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology (2009) 3.42
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
WNT/beta-catenin signaling in liver health and disease. Hepatology (2007) 3.26
Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology (2007) 3.22
Bacterial translocation (BT) in cirrhosis. Hepatology (2005) 3.07
Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A (2008) 2.98
Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology (2011) 2.90
Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut (2005) 2.90
Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest (2011) 2.83
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med (2009) 2.73
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene (2007) 2.71
A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology (2007) 2.66
Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst (2011) 2.63
Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res (2010) 2.62
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res (2006) 2.61
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol (2009) 2.56
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev (2007) 2.52
Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg (2006) 2.52
Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg (1991) 2.46
Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol (2013) 2.44
Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology (2007) 2.42
Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol (2010) 2.38
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol (2003) 2.36
Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res (1989) 2.35
Liver stem cells and hepatocellular carcinoma. Hepatology (2009) 2.27
Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci U S A (1987) 2.24
Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery (2006) 2.24
Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem (2005) 2.21
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Activation of fibroblasts in cancer stroma. Exp Cell Res (2010) 2.19
Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol (2000) 2.18
P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology (2002) 2.18
beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer (2001) 2.17
Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol (2007) 2.16
HAb18G/CD147 promotes activation of hepatic stellate cells and is a target for antibody therapy of liver fibrosis. J Hepatol (2012) 2.15
IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep (2009) 2.14
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci (2002) 2.10
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology (2010) 2.03
Hedgehog signaling maintains resident hepatic progenitors throughout life. Am J Physiol Gastrointest Liver Physiol (2005) 2.02
Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res (2010) 2.02
Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther (2008) 2.00
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg (2003) 1.97
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology (2009) 1.95
Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol (2011) 1.93